U.S. Ophthalmic Surgical Systems Market, April 2014
U.S. Ophthalmic Surgical Systems Market, April 2014
$3,750.00
This report discusses common ophthalmic diseases/disorders, prevalence, estimated U.S. procedure volumes, leading energy-based (laser and phacoemulsification, or “phaco”) ophthalmic surgical systems and their features, and novel technologies. A detailed U.S. market analysis, competitive analysis, and company profiles of selected U.S. competitors are also provided.
Publisher: Meddevicetracker
- Highlights
- Description
- Contents
The U.S. market for energy-based ophthalmic surgical systems is large and robust, totaling more than $1.6 billion, and is expected to experience healthy, moderate
growth over the next half-decade.
This report discusses common ophthalmic diseases/disorders, prevalence, estimated U.S. procedure volumes, leading energy-based (laser and phacoemulsification, or “phaco”) ophthalmic surgical systems and their features, and novel technologies. A detailed U.S. market analysis, competitive analysis, and company profiles of selected U.S. competitors are also provided.
In the United States (U.S.), serious ophthalmic disease affects more than 35 million. This number is expected to significantly increase due to the aging of the population and disorders such as diabetes that may result in progressive vision loss. Alarmingly, the number of patients with cataracts is expected to increase significantly over the next decade, contributing a substantial increase in the number of cataract surgeries.
The development of new, minimally invasive energy-based (laser/phacoemulsification or “phaco”) technologies is providing safe and effective, medically necessary, vision-saving treatment to millions of patients, particularly those with cataracts who also seek vision correction surgery. Meanwhile, non-medically necessary, high-cost refractive surgery, such as laser in situ keratomileusis (LASIK) vision correction, continues to increase despite several setbacks.
Overall, more than an estimated 5.5 million directed-energy based (laser/phaco) ophthalmic procedures, including cataract laser surgery, diabetic retinopathy laser surgery, glaucoma/laser trabeculoplasty and laser-based vision correction surgery, were estimated to have been performed in the U.S. in 2013. The advancement of safer and more cost-effective laser-based technologies, such as femtosecond laser cataract surgery and other technological improvements, are expected to improve patient outcomes and drive ophthalmic surgical procedures and market growth over the next half-decade.
For the purposes of this report, the U.S. market for ophthalmic surgical systems includes sales derived from laser and phaco systems for vision correction and the minimally invasive treatment of cataracts, glaucoma, retinal, and other ophthalmic disorders. In addition to ophthalmic surgical systems sales, the market forecast includes revenues derived from surgical accessories/instruments and disposables utilized in minimally invasive directed energy-based ophthalmic surgery. In 2013, the U.S. ophthalmic surgical systems market was valued at approximately $1,695.8 million. Over the forecast period covered by this report, total sales in this market are expected to increase at a compound annual rate of 5.9%, reaching an estimated $2,256.4 million in the year 2018.
This dynamic, new report from Medtech Insight includes analyses of products, current/forecast markets, competitors, and opportunities in the U.S. ophthalmic surgical systems market. Covered topics in this report include an overview of common ophthalmic diseases/disorders and therapies; U.S. procedure volumes; laser/phaco/energy-based surgical systems, next-generation laser-based systems and emerging technologies; and company profiles.
TABLE OF CONTENTS
EXECUTIVE SUMMARY…………………………………………………………………………. ES-1
i. Clinical Overview…………………………………………………………………. ES-1
a. Age-Related Macular Degeneration …………………………. ES-1
b. Cataracts……………………………………………………………… ES-3
c. Diabetic Retinopathy ……………………………………………… ES-3
d. Glaucoma…………………………………………………………….. ES-4
e. Refractive Errors …………………………………………………… ES-4
ii. Market ……………………………………………………………………………….. ES-4
iii. Methodology……………………………………………………………………….. ES-6
Exhibit ES-1: 2013, Estimated U.S. Prevalence of Selected Ophthalmic Conditions………………………………………………………………………… ES-2
Exhibit ES-2: U.S. Ophthalmic Surgical Systems, Market Forecast, 2013-2018………………………………………………………………………… ES-7
1. U.S. OPHTHALMIC SURGICAL SYSTEMS MARKET …………………………. 1-1
1.1 Clinical Overview……………………………………………………………………. 1-1
1.1.1 Age-Related Macular Degeneration ……………………………. 1-1
1.2.5 Refractive Surgery………………………………………………….. 1-22
1.2.5.1 Laser-Based Vision Correction…………………… 1-22
1.2.5.2 Photorefractive Keratectomy ……………………… 1-23
1.2.5.3 Laser In Situ Keratomileusis………………………. 1-23
1.2.5.4 Laser Epithelial Keratomileusis ………………….. 1-24
1.2.5.5 Custom Laser In Situ Keratomileusis ………….. 1-24
1.2.5.6 Photoablative Inlay Laser In Situ Keratomileusis…………………………………………. 1-25
1.2.5.7 Procedure Volumes Forecast…………………….. 1-25
1.3 Market Analysis ……………………………………………………………………. 1-26
1.3.1 Market Forecast …………………………………………………….. 1-26
1.4 Competitive Analysis …………………………………………………………….. 1-29
1.4.1 Market Share…………………………………………………………. 1-29
Exhibit 1-1: 2013, Estimated U.S. Prevalence of Selected Ophthalmic Conditions ……………………………………………………………. 1-2
Exhibit 1-2: Laser Therapy for Age-Related Macular Degeneration, U.S. Procedure Volumes Forecast, 2011-2018 …………………………. 1-10
Exhibit 1-3: Cataract Surgery, U.S. Procedure Volumes Forecast, 2011-2018 (in Thousands) …………………………………………………….. 1-15
Exhibit 1-4: Diabetic Retinopathy Laser Surgery, U.S. Procedure Volumes Forecast, 2011-2018 (in Thousands)………………………….. 1-18
Exhibit 1-5: Glaucoma Surgery, U.S. Procedure Volumes Forecast, 2011-2018 (in Thousands) …………………………………………………….. 1-21
Exhibit 1-6: Refractive Laser Surgery, U.S. Procedure Volumes Forecast, 2011-2018 (in Thousands) …………………………………………………….. 1-27
Exhibit 1-7: Selected Market Drivers and Limiters………………………………………. 1-30
Exhibit 1-8: U.S. Ophthalmic Surgical Systems, Market Forecast, 2013-2018 …………………………………………………………………………… 1-31
Exhibit 1-9: 2013, U.S. Ophthalmic Surgical Systems Market, Estimated Percentage of Sales, by Application …………………………. 1-32
Exhibit 1-10: 2013, Leading Competitors in the U.S. Ophthalmic Surgical Systems Market and Applications for Leading Products……………… 1-34
Exhibit 1-11: 2013, U.S. Ophthalmic Surgical Systems Market, Share by Supplier…………………………………………………………………. 1-38
2. COMPANY PROFILES…………………………………………………………………….. 2-1
2.1 Abbott Laboratories ………………………………………………………………… 2-1
2.1.1 Background …………………………………………………………….. 2-1
2.1.2 Abbott Medical Optics Division …………………………………… 2-1
2.1.3 Acquisitions …………………………………………………………….. 2-2
2.1.4 Surgical Systems……………………………………………………… 2-3
2.1.5 Medical Optics Revenues………………………………………….. 2-5
2.1.6 Selected Financials ………………………………………………….. 2-5
2.2 Carl Zeiss Meditec AG…………………………………………………………….. 2-6
2.2.1 Background …………………………………………………………….. 2-6
2.2.2 Carl Zeiss Ophthalmology Business……………………………. 2-6
2.2.3 Acquisitions …………………………………………………………….. 2-7
2.2.4 Surgical Systems……………………………………………………… 2-7
2.2.5 Ophthalmology Segment Revenues……………………………. 2-9
2.2.6 Selected Financials ………………………………………………….. 2-9
2.3 IRIDEX Corporation………………………………………………………………. 2-10
2.3.1 Background …………………………………………………………… 2-10
2.3.2 Acquisitions/Divestitures………………………………………….. 2-10
2.3.3 Surgical Systems……………………………………………………. 2-11
2.3.4 Selected Financials ………………………………………………… 2-13
2.4 Lumenis Ltd…………………………………………………………………………. 2-13
2.4.1 Background …………………………………………………………… 2-13
2.4.2 Ophthalmic Division………………………………………………… 2-14
2.4.3 Surgical Systems……………………………………………………. 2-14
2.4.4 Ophthalmic Division Revenues…………………………………. 2-16
2.4.5 Selected Financials ………………………………………………… 2-17
2.5 Novartis ………………………………………………………………………………. 2-17
2.5.1 Background …………………………………………………………… 2-17
2.5.2 Alcon Division………………………………………………………… 2-17
2.5.3 Acquisitions …………………………………………………………… 2-18
2.5.4 Surgical Systems……………………………………………………. 2-19
2.5.5 Alcon Division Revenues…………………………………………. 2-24
2.5.6 Selected Financials ………………………………………………… 2-25
2.6 Valeant Pharmaceuticals……………………………………………………….. 2-25
2.6.1 Background …………………………………………………………… 2-25
2.6.2 Bausch and Lomb ………………………………………………….. 2-26
2.6.3 Acquisitions …………………………………………………………… 2-26
2.6.4 Surgical Systems……………………………………………………. 2-27
2.6.5 Bausch + Lomb Revenues ………………………………………. 2-30
2.6.6 Selected Financials ………………………………………………… 2-30
APPENDIX: COMPANY LISTING
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Congestive Heart Failure Pulse Survey 
Sign up to the